Computerized physician order entry‐based system to prevent HBV reactivation in patients treated with biologic agents: The PRESCRIB project
Computerized physician order entry (CPOE) applications are widely used to prevent medical errors. In our center, a CPOE system has been in use since 2009 on both the inpatient and outpatient levels. A new and simple alert was introduced in the CPOE system to notify healthcare providers of the potent...
Gespeichert in:
Veröffentlicht in: | Hepatology (Baltimore, Md.) Md.), 2014-07, Vol.60 (1), p.106-113 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 113 |
---|---|
container_issue | 1 |
container_start_page | 106 |
container_title | Hepatology (Baltimore, Md.) |
container_volume | 60 |
creator | Sampedro, Blanca Hernández‐López, Cándido Ferrandiz, José Ramón Illaro, Aitziber Fábrega, Emilio Cuadrado, Antonio Iruzubieta, Paula Menéndez, Susana Cabezas, Joaquín Crespo, Javier |
description | Computerized physician order entry (CPOE) applications are widely used to prevent medical errors. In our center, a CPOE system has been in use since 2009 on both the inpatient and outpatient levels. A new and simple alert was introduced in the CPOE system to notify healthcare providers of the potential risk of viral reactivation when prescribing biological therapies, thereby facilitating the request for a serological profile (hepatitis B surface antigen [HBsAg], anti‐HBc, and anti‐HBs) in patients who have not had these tests. Between May 2012 and May 2013, a total of 1,076 patients undergoing biological treatment were included in the implementation of the CPOE in our hospital, resulting in the identification of 4 HBsAg‐positive and 69 anti‐HBc‐positive/HBsAg‐negative patients, two of them with positive viral loads. Since the implementation of this alert system, over 90% of patients who were prescribed a biological drug (BD) have undergone serological screening to detect hepatitis B virus (HBV) infection. The use of the alert system has increased the screening rate from less than 50% to 94% for HBsAg and from less than 30% to 85% for anti‐HBc in patients for whom a BD is prescribed. Six patients received prophylactic antiviral therapy. No patient had HBV reactivation. Conclusion: This study demonstrates the feasibility of implementing a CPOE system that has allowed our hospital to increase the rate of HBV screening. Its use has facilitated the identification of patients at high risk for HBV reactivation and permitted physicians to prescribe prophylactic measures according to current guidelines. (Hepatology 2014;106–113) |
doi_str_mv | 10.1002/hep.27103 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1542003561</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1542003561</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4233-63d72e4ccc5c71226f8753b65474202530a74d5c708a4cda3a76446178e36203</originalsourceid><addsrcrecordid>eNp1kc1uEzEURi0EoqGw4AWQJTawmPb6bzxh10aBVKpEVSK2I8dz0ziaGQ-2p1VY9QG64Bl5EhxSWCCx8bV0zv1s6SPkNYMTBsBPNziccM1APCETprguhFDwlEyAayimTEyPyIsYtwAwlbx6To64VJVSICbkYea7YUwY3Hds6LDZRWed6akPDQaKfQq7n_c_ViZmGncxYUeTp0PA28zo4vwrDWhscrcmOd9T19Mh3zKLNGWS8tqdSxu6cr71N85Sc7OHH-hyg_Tqev5ldn1xnvP8Fm16SZ6tTRvx1eM8JsuP8-VsUVx-_nQxO7ssrORCFKVoNEdprVVWM87LdaWVWJVKasmBKwFGyyYzqIy0jRFGl1KWTFcoSg7imLw7xOZnv40YU925aLFtTY9-jDVTOQaEKllW3_6jbv0Y-vy5vQWyrPKRrfcHywYfY8B1PQTXmbCrGdT7hurcUP27oey-eUwcVx02f80_lWTh9CDcuRZ3_0-qF_OrQ-QvNeea9A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1540468404</pqid></control><display><type>article</type><title>Computerized physician order entry‐based system to prevent HBV reactivation in patients treated with biologic agents: The PRESCRIB project</title><source>MEDLINE</source><source>Wiley Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Sampedro, Blanca ; Hernández‐López, Cándido ; Ferrandiz, José Ramón ; Illaro, Aitziber ; Fábrega, Emilio ; Cuadrado, Antonio ; Iruzubieta, Paula ; Menéndez, Susana ; Cabezas, Joaquín ; Crespo, Javier</creator><creatorcontrib>Sampedro, Blanca ; Hernández‐López, Cándido ; Ferrandiz, José Ramón ; Illaro, Aitziber ; Fábrega, Emilio ; Cuadrado, Antonio ; Iruzubieta, Paula ; Menéndez, Susana ; Cabezas, Joaquín ; Crespo, Javier</creatorcontrib><description>Computerized physician order entry (CPOE) applications are widely used to prevent medical errors. In our center, a CPOE system has been in use since 2009 on both the inpatient and outpatient levels. A new and simple alert was introduced in the CPOE system to notify healthcare providers of the potential risk of viral reactivation when prescribing biological therapies, thereby facilitating the request for a serological profile (hepatitis B surface antigen [HBsAg], anti‐HBc, and anti‐HBs) in patients who have not had these tests. Between May 2012 and May 2013, a total of 1,076 patients undergoing biological treatment were included in the implementation of the CPOE in our hospital, resulting in the identification of 4 HBsAg‐positive and 69 anti‐HBc‐positive/HBsAg‐negative patients, two of them with positive viral loads. Since the implementation of this alert system, over 90% of patients who were prescribed a biological drug (BD) have undergone serological screening to detect hepatitis B virus (HBV) infection. The use of the alert system has increased the screening rate from less than 50% to 94% for HBsAg and from less than 30% to 85% for anti‐HBc in patients for whom a BD is prescribed. Six patients received prophylactic antiviral therapy. No patient had HBV reactivation. Conclusion: This study demonstrates the feasibility of implementing a CPOE system that has allowed our hospital to increase the rate of HBV screening. Its use has facilitated the identification of patients at high risk for HBV reactivation and permitted physicians to prescribe prophylactic measures according to current guidelines. (Hepatology 2014;106–113)</description><identifier>ISSN: 0270-9139</identifier><identifier>EISSN: 1527-3350</identifier><identifier>DOI: 10.1002/hep.27103</identifier><identifier>PMID: 24585503</identifier><identifier>CODEN: HPTLD9</identifier><language>eng</language><publisher>United States: Wolters Kluwer Health, Inc</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antiviral Agents - therapeutic use ; Biological Factors - adverse effects ; Child ; Feasibility Studies ; Female ; Hepatitis ; Hepatitis B Antibodies - blood ; Hepatitis B Surface Antigens - blood ; Hepatitis B, Chronic - epidemiology ; Hepatitis B, Chronic - immunology ; Hepatitis B, Chronic - prevention & control ; Hepatology ; Hospitals ; Humans ; Immunosuppressive Agents - adverse effects ; Male ; Medical errors ; Medical Order Entry Systems - organization & administration ; Middle Aged ; Order entry ; Physicians ; Practice Patterns, Physicians' - organization & administration ; Prospective Studies ; Risk Factors ; Virus Activation - drug effects ; Virus Activation - immunology ; Young Adult</subject><ispartof>Hepatology (Baltimore, Md.), 2014-07, Vol.60 (1), p.106-113</ispartof><rights>2014 by the American Association for the Study of Liver Diseases</rights><rights>2014 by the American Association for the Study of Liver Diseases.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4233-63d72e4ccc5c71226f8753b65474202530a74d5c708a4cda3a76446178e36203</citedby><cites>FETCH-LOGICAL-c4233-63d72e4ccc5c71226f8753b65474202530a74d5c708a4cda3a76446178e36203</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhep.27103$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhep.27103$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24585503$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sampedro, Blanca</creatorcontrib><creatorcontrib>Hernández‐López, Cándido</creatorcontrib><creatorcontrib>Ferrandiz, José Ramón</creatorcontrib><creatorcontrib>Illaro, Aitziber</creatorcontrib><creatorcontrib>Fábrega, Emilio</creatorcontrib><creatorcontrib>Cuadrado, Antonio</creatorcontrib><creatorcontrib>Iruzubieta, Paula</creatorcontrib><creatorcontrib>Menéndez, Susana</creatorcontrib><creatorcontrib>Cabezas, Joaquín</creatorcontrib><creatorcontrib>Crespo, Javier</creatorcontrib><title>Computerized physician order entry‐based system to prevent HBV reactivation in patients treated with biologic agents: The PRESCRIB project</title><title>Hepatology (Baltimore, Md.)</title><addtitle>Hepatology</addtitle><description>Computerized physician order entry (CPOE) applications are widely used to prevent medical errors. In our center, a CPOE system has been in use since 2009 on both the inpatient and outpatient levels. A new and simple alert was introduced in the CPOE system to notify healthcare providers of the potential risk of viral reactivation when prescribing biological therapies, thereby facilitating the request for a serological profile (hepatitis B surface antigen [HBsAg], anti‐HBc, and anti‐HBs) in patients who have not had these tests. Between May 2012 and May 2013, a total of 1,076 patients undergoing biological treatment were included in the implementation of the CPOE in our hospital, resulting in the identification of 4 HBsAg‐positive and 69 anti‐HBc‐positive/HBsAg‐negative patients, two of them with positive viral loads. Since the implementation of this alert system, over 90% of patients who were prescribed a biological drug (BD) have undergone serological screening to detect hepatitis B virus (HBV) infection. The use of the alert system has increased the screening rate from less than 50% to 94% for HBsAg and from less than 30% to 85% for anti‐HBc in patients for whom a BD is prescribed. Six patients received prophylactic antiviral therapy. No patient had HBV reactivation. Conclusion: This study demonstrates the feasibility of implementing a CPOE system that has allowed our hospital to increase the rate of HBV screening. Its use has facilitated the identification of patients at high risk for HBV reactivation and permitted physicians to prescribe prophylactic measures according to current guidelines. (Hepatology 2014;106–113)</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Biological Factors - adverse effects</subject><subject>Child</subject><subject>Feasibility Studies</subject><subject>Female</subject><subject>Hepatitis</subject><subject>Hepatitis B Antibodies - blood</subject><subject>Hepatitis B Surface Antigens - blood</subject><subject>Hepatitis B, Chronic - epidemiology</subject><subject>Hepatitis B, Chronic - immunology</subject><subject>Hepatitis B, Chronic - prevention & control</subject><subject>Hepatology</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Immunosuppressive Agents - adverse effects</subject><subject>Male</subject><subject>Medical errors</subject><subject>Medical Order Entry Systems - organization & administration</subject><subject>Middle Aged</subject><subject>Order entry</subject><subject>Physicians</subject><subject>Practice Patterns, Physicians' - organization & administration</subject><subject>Prospective Studies</subject><subject>Risk Factors</subject><subject>Virus Activation - drug effects</subject><subject>Virus Activation - immunology</subject><subject>Young Adult</subject><issn>0270-9139</issn><issn>1527-3350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1uEzEURi0EoqGw4AWQJTawmPb6bzxh10aBVKpEVSK2I8dz0ziaGQ-2p1VY9QG64Bl5EhxSWCCx8bV0zv1s6SPkNYMTBsBPNziccM1APCETprguhFDwlEyAayimTEyPyIsYtwAwlbx6To64VJVSICbkYea7YUwY3Hds6LDZRWed6akPDQaKfQq7n_c_ViZmGncxYUeTp0PA28zo4vwrDWhscrcmOd9T19Mh3zKLNGWS8tqdSxu6cr71N85Sc7OHH-hyg_Tqev5ldn1xnvP8Fm16SZ6tTRvx1eM8JsuP8-VsUVx-_nQxO7ssrORCFKVoNEdprVVWM87LdaWVWJVKasmBKwFGyyYzqIy0jRFGl1KWTFcoSg7imLw7xOZnv40YU925aLFtTY9-jDVTOQaEKllW3_6jbv0Y-vy5vQWyrPKRrfcHywYfY8B1PQTXmbCrGdT7hurcUP27oey-eUwcVx02f80_lWTh9CDcuRZ3_0-qF_OrQ-QvNeea9A</recordid><startdate>201407</startdate><enddate>201407</enddate><creator>Sampedro, Blanca</creator><creator>Hernández‐López, Cándido</creator><creator>Ferrandiz, José Ramón</creator><creator>Illaro, Aitziber</creator><creator>Fábrega, Emilio</creator><creator>Cuadrado, Antonio</creator><creator>Iruzubieta, Paula</creator><creator>Menéndez, Susana</creator><creator>Cabezas, Joaquín</creator><creator>Crespo, Javier</creator><general>Wolters Kluwer Health, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201407</creationdate><title>Computerized physician order entry‐based system to prevent HBV reactivation in patients treated with biologic agents: The PRESCRIB project</title><author>Sampedro, Blanca ; Hernández‐López, Cándido ; Ferrandiz, José Ramón ; Illaro, Aitziber ; Fábrega, Emilio ; Cuadrado, Antonio ; Iruzubieta, Paula ; Menéndez, Susana ; Cabezas, Joaquín ; Crespo, Javier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4233-63d72e4ccc5c71226f8753b65474202530a74d5c708a4cda3a76446178e36203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Biological Factors - adverse effects</topic><topic>Child</topic><topic>Feasibility Studies</topic><topic>Female</topic><topic>Hepatitis</topic><topic>Hepatitis B Antibodies - blood</topic><topic>Hepatitis B Surface Antigens - blood</topic><topic>Hepatitis B, Chronic - epidemiology</topic><topic>Hepatitis B, Chronic - immunology</topic><topic>Hepatitis B, Chronic - prevention & control</topic><topic>Hepatology</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Immunosuppressive Agents - adverse effects</topic><topic>Male</topic><topic>Medical errors</topic><topic>Medical Order Entry Systems - organization & administration</topic><topic>Middle Aged</topic><topic>Order entry</topic><topic>Physicians</topic><topic>Practice Patterns, Physicians' - organization & administration</topic><topic>Prospective Studies</topic><topic>Risk Factors</topic><topic>Virus Activation - drug effects</topic><topic>Virus Activation - immunology</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sampedro, Blanca</creatorcontrib><creatorcontrib>Hernández‐López, Cándido</creatorcontrib><creatorcontrib>Ferrandiz, José Ramón</creatorcontrib><creatorcontrib>Illaro, Aitziber</creatorcontrib><creatorcontrib>Fábrega, Emilio</creatorcontrib><creatorcontrib>Cuadrado, Antonio</creatorcontrib><creatorcontrib>Iruzubieta, Paula</creatorcontrib><creatorcontrib>Menéndez, Susana</creatorcontrib><creatorcontrib>Cabezas, Joaquín</creatorcontrib><creatorcontrib>Crespo, Javier</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology (Baltimore, Md.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sampedro, Blanca</au><au>Hernández‐López, Cándido</au><au>Ferrandiz, José Ramón</au><au>Illaro, Aitziber</au><au>Fábrega, Emilio</au><au>Cuadrado, Antonio</au><au>Iruzubieta, Paula</au><au>Menéndez, Susana</au><au>Cabezas, Joaquín</au><au>Crespo, Javier</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Computerized physician order entry‐based system to prevent HBV reactivation in patients treated with biologic agents: The PRESCRIB project</atitle><jtitle>Hepatology (Baltimore, Md.)</jtitle><addtitle>Hepatology</addtitle><date>2014-07</date><risdate>2014</risdate><volume>60</volume><issue>1</issue><spage>106</spage><epage>113</epage><pages>106-113</pages><issn>0270-9139</issn><eissn>1527-3350</eissn><coden>HPTLD9</coden><abstract>Computerized physician order entry (CPOE) applications are widely used to prevent medical errors. In our center, a CPOE system has been in use since 2009 on both the inpatient and outpatient levels. A new and simple alert was introduced in the CPOE system to notify healthcare providers of the potential risk of viral reactivation when prescribing biological therapies, thereby facilitating the request for a serological profile (hepatitis B surface antigen [HBsAg], anti‐HBc, and anti‐HBs) in patients who have not had these tests. Between May 2012 and May 2013, a total of 1,076 patients undergoing biological treatment were included in the implementation of the CPOE in our hospital, resulting in the identification of 4 HBsAg‐positive and 69 anti‐HBc‐positive/HBsAg‐negative patients, two of them with positive viral loads. Since the implementation of this alert system, over 90% of patients who were prescribed a biological drug (BD) have undergone serological screening to detect hepatitis B virus (HBV) infection. The use of the alert system has increased the screening rate from less than 50% to 94% for HBsAg and from less than 30% to 85% for anti‐HBc in patients for whom a BD is prescribed. Six patients received prophylactic antiviral therapy. No patient had HBV reactivation. Conclusion: This study demonstrates the feasibility of implementing a CPOE system that has allowed our hospital to increase the rate of HBV screening. Its use has facilitated the identification of patients at high risk for HBV reactivation and permitted physicians to prescribe prophylactic measures according to current guidelines. (Hepatology 2014;106–113)</abstract><cop>United States</cop><pub>Wolters Kluwer Health, Inc</pub><pmid>24585503</pmid><doi>10.1002/hep.27103</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0270-9139 |
ispartof | Hepatology (Baltimore, Md.), 2014-07, Vol.60 (1), p.106-113 |
issn | 0270-9139 1527-3350 |
language | eng |
recordid | cdi_proquest_miscellaneous_1542003561 |
source | MEDLINE; Wiley Journals; EZB-FREE-00999 freely available EZB journals |
subjects | Adolescent Adult Aged Aged, 80 and over Antiviral Agents - therapeutic use Biological Factors - adverse effects Child Feasibility Studies Female Hepatitis Hepatitis B Antibodies - blood Hepatitis B Surface Antigens - blood Hepatitis B, Chronic - epidemiology Hepatitis B, Chronic - immunology Hepatitis B, Chronic - prevention & control Hepatology Hospitals Humans Immunosuppressive Agents - adverse effects Male Medical errors Medical Order Entry Systems - organization & administration Middle Aged Order entry Physicians Practice Patterns, Physicians' - organization & administration Prospective Studies Risk Factors Virus Activation - drug effects Virus Activation - immunology Young Adult |
title | Computerized physician order entry‐based system to prevent HBV reactivation in patients treated with biologic agents: The PRESCRIB project |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T05%3A24%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Computerized%20physician%20order%20entry%E2%80%90based%20system%20to%20prevent%20HBV%20reactivation%20in%20patients%20treated%20with%20biologic%20agents:%20The%20PRESCRIB%20project&rft.jtitle=Hepatology%20(Baltimore,%20Md.)&rft.au=Sampedro,%20Blanca&rft.date=2014-07&rft.volume=60&rft.issue=1&rft.spage=106&rft.epage=113&rft.pages=106-113&rft.issn=0270-9139&rft.eissn=1527-3350&rft.coden=HPTLD9&rft_id=info:doi/10.1002/hep.27103&rft_dat=%3Cproquest_cross%3E1542003561%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1540468404&rft_id=info:pmid/24585503&rfr_iscdi=true |